News | Antiplatelet and Anticoagulation Therapies | December 12, 2017

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks

Mayo Clinic research suggests atrial fibrillation patients must carefully choose anticoagulants with their healthcare provider

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks

December 12, 2017 — Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke and increased risks of kidney function decline or failure.

Their study, published online in the Journal of the American College of Cardiology, is the most recent in a series of studies seeking to determine the safety and efficacy of non-vitamin K antagonist oral anticoagulants versus the long-standard warfarin. Patients with atrial fibrillation – a potent risk factor for stroke ─ commonly take these medications.

“Kidney function decline in patients taking oral anticoagulant drugs is an important topic that has been overlooked in previous clinical trials,” said lead author Xiaoxi Yao, Ph.D. “Even our past work at Mayo Clinic has been primarily focused on risks for stroke or bleeding.”

However, she and the study senior author, Peter Noseworthy, M.D., a Mayo Clinic cardiologist, along with the rest of their team, felt that the issue was worth pursuing.

“Our study demonstrated that renal function decline is very common among atrial fibrillation patients on blood thinners,” said Yao. “About 1 in 4 patients had significantly reduced kidney function within two years of being on any of these medications, and 1 in 7 patients had acute kidney injury.”

The reduced kidney function could lead to kidney failure, dialysis and potentially death. Finding this, the researchers went a step further, trying to determine if the type of medication made a difference.

“In general, patients with atrial fibrillation taking blood-thinning medications tend to have declining kidney function over time,” said Noseworthy. “However, our findings indicate that the non-vitamin K antagonist oral anticoagulants as a group are associated with less injury to kidneys than warfarin.”

To come to these conclusions, the researchers studied the deidentified records of 9,769 patients from the OptumLabs Data Warehouse. These patients had atrial fibrillation and started taking oral anticoagulants ─ apixaban, dabigatran, rivaroxaban or warfarin ─ sometime between Oct. 1, 2010, and April 30, 2016.

The team looked at four indicators of kidney function:

  • Thirty percent decline (or more) in glomerular filtration rate (how well the kidneys filter waste);
  • Doubled serum creatinine level (a waste product that should be filtered by the kidneys);
  • Acute kidney injury; and
  • Kidney failure.

They found that the cumulative risk of one of these four events occurring within two years of beginning the medication was 24.4 percent, 4 percent, 14.8 percent and 1.7 percent, respectively, proving that kidney function decline is common in these patients.

However, the researchers took it a step further and separated out the patients taking non-vitamin K antagonist oral anticoagulants from those taking warfarin.

“We found that non-vitamin K antagonist oral anticoagulants, as a group, were associated with reduced risk of adverse kidney outcomes,” said Noseworthy.

“Patients with atrial fibrillation already face a high risk of kidney disease, perhaps because many such patients have risk factors, such as advanced age, diabetes and hypertension,” said Yao. “Many drugs these patients are taking rely on kidney function for drug elimination. Therefore, it is particularly important for these patients to choose a drug that minimizes the impact on kidneys. Since non-vitamin K antagonist oral anticoagulants have a different drug mechanism than warfarin, researchers have hypothesized that non-vitamin K antagonist oral anticoagulants may be related to better renal outcomes. Our study is among the first few studies confirming this hypothesis.”

Their findings have important implications for medical practice, she said, and Noseworthy confirms.

“Just as I do with my own patients, I encourage conversations on these risks and benefits between patients and their providers,” said Noseworthy.“Each patient’s situation is different, so each medication decision must be made based on the individual’s lifestyle and diet, other illnesses and medications, out-of-pocket costs, and so forth.”

Both he and Yao encourage healthcare providers to regularly follow up and monitor kidney function in their patients taking anticoagulants. They urge providers to make efforts to prevent or slow kidney function decline, as well as adjust drug dosage based on the change of kidney function. And, as with all medications, Noseworthy cautions patients to never stop or change any medication dosage without consulting with their healthcare providers.

The rest of the Mayo Clinic research team members are:

  • Bernard Gersh, M.B., Ch.B., D.Phil.;
  • Karl Nath, M.D.;
  • Lindsey Sangaralingham; and
  • Nilay Shah, Ph.D.

The research team also included Navdeep Tangri, M.D., Ph.D., from the University of Manitoba, Canada.

For more information: www.onlinejacc.org

 

Related NOAC Content:

Newer Anticoagulant Reduces Major Bleeds in AF Ablation

Advantages and Disadvantages of Novel Oral Anticoagulants

First Head-to-Head Comparison of Novel Oral Anticoagulants in Matched Population for Costs, Resource Utilization

Related Content

Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init